Insider Transactions in Q1 2023 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2023
|
Adam Morgan Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,879
+50.0%
|
-
|
|
Jan 13
2023
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-7.75%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+10.24%
|
-
|
|
Jan 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,013
-4.39%
|
$3,039
$3.17 P/Share
|
|
Jan 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.14%
|
-
|
|
Jan 13
2023
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-4.49%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+6.12%
|
-
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-2.85%
|
$15,657
$3.17 P/Share
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,767
+5.11%
|
-
|
|
Jan 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-7.14%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+9.49%
|
-
|